CRA-2059

• Description:

  CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ) [1][2].

• UNSPSC:

  12352005

• Target:

  Ser/Thr Protease

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cra-2059.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NC (NC1=CC=C (CNC (N2CCN (C (O[C@@H]3COC4[C@H] (OC (N5CCN (C (NCC6=CC=C (NC (N) =N) C=C6) =O) CC5) =O) COC34) =O) CC2) =O) C=C1) =N

• Molecular Formula:

  C34H46N12O8

• Molecular Weight:

  750.80

• References & Citations:

  [1]Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059) : an open-label pilot study. Aliment Pharmacol Ther. 2002;16 (3) :407-413.|[2]Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem. 2003;384 (12) :1605-1611.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  256649-36-2